46.32

2.59% +1.27

Crinetics Pharmaceuticals Inc (CRNX)

개요 뉴스 가격 이력 옵션 체인 Financials CRNX 왜 하락? 토론 예측

전일 마감가:

$45.05

열려 있는:

$45.61

하루 거래량:

108.66K

시가총액:

$3.64B

수익:

$4.72M

순이익/손실:

$-214.53M

주가수익비율:

-13.58

EPS:

-3.41

순현금흐름:

$-171.00M

1주 성능:

+9.29%

1개월 성능:

+0.47%

6개월 성능:

+58.28%

1년 성능:

+121.56%

1일 변동 폭

$44.84

$46.45

52주 변동 폭

$15.76

$49.58

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

명칭

Crinetics Pharmaceuticals Inc

부문

Healthcare (1193)

산업

Biotechnology (685)

전화

858-450-6464

주소

10222 Barnes Canyon Road, Building 2, San Diego, CA

직원

트위터

@Crinetics

다음 수익 날짜

2024-05-02

최신 SEC 제출 서류

CRNX's Discussions on Twitter

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-01-16	개시	Morgan Stanley	Overweight
2023-12-21	개시	Jefferies	Hold
2023-11-20	재개	JP Morgan	Overweight
2023-10-24	재개	Cantor Fitzgerald	Overweight
2023-08-31	개시	Oppenheimer	Outperform
2023-04-24	개시	Piper Sandler	Overweight
2023-03-30	개시	Robert W. Baird	Outperform
2021-11-30	개시	JMP Securities	Mkt Outperform
2021-11-23	개시	Evercore ISI	Outperform
2021-06-18	업그레이드	JP Morgan	Neutral → Overweight
2019-12-23	개시	ROTH Capital	Buy
2019-02-14	개시	H.C. Wainwright	Buy
2018-08-13	개시	JP Morgan	Neutral
2018-08-13	개시	Leerink Partners	Outperform
2018-08-13	개시	Piper Jaffray	Overweight

모두보기

Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Zacks Investment Research

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

Zacks Investment Research

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

Zacks Investment Research

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday

Benzinga

Crinetics Pharmaceuticals Inc (CRNX) 재무 분석

Crinetics Pharmaceuticals Inc (CRNX) 매출 2024

CRNX은 2023-09-30 종료 분기에 대해 매출(지난 12개월)이 4.72M 달러로 보고했으며, 전년대비 -7.52% 감소했습니다.

Crinetics Pharmaceuticals Inc (CRNX) 순이익 2024

CRNX은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -214.53M 달러로 보고했으며, 전년대비 -30.88% 감소했습니다.

Crinetics Pharmaceuticals Inc (CRNX) 현금흐름 2024

2023-12-31 종료 분기에 CRNX은 현금흐름(지난 12개월)으로 -171.00M 달러를 기록했으며, 전년 대비 -46.32% 감소했습니다.

Crinetics Pharmaceuticals Inc (CRNX) 주당 순이익 2024

CRNX이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -3.70달러이며, 전년 대비 -17.09% 감소했습니다.

Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Struthers Richard Scott	President & CEO	Apr 15 '24	Option Exercise	1.91	20,000	38,200	257,835
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Sale	44.47	14,375	639,256	27,786
Struthers Richard Scott	President & CEO	Apr 04 '24	Option Exercise	9.28	40,951	380,025	278,786
Struthers Richard Scott	President & CEO	Apr 04 '24	Sale	49.17	40,951	2,013,561	237,835
Okey Stephanie	Director	Mar 28 '24	Option Exercise	18.29	17,500	320,075	23,500
Okey Stephanie	Director	Mar 28 '24	Sale	46.38	17,500	811,650	6,000
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Option Exercise	23.98	30,000	719,400	84,939
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Sale	44.31	32,359	1,433,675	52,580
Fust Matthew K	Director	Mar 20 '24	Option Exercise	20.92	60,000	1,254,975	36,036
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Option Exercise	16.89	14,375	242,794	38,500